The markers of bone turnover in patients with lung cancer

Journal of the National Medical Association

Volumn 100, Issue 4, 2008, Pages 425-428

  Dane, Faysal ^a   Turk, H Mehmet ^b   Sevinc, Alper ^b   Buyukberber, Suleyman ^c   Camci, Celalettin ^b   Tarakcioglu, Mehmet ^b  

^a MARMARA UNIVERSITY   (Turkey)

^b GAZIANTEP UNIVERSITY   (Turkey)

^c GAZI UNIVERSITY   (Turkey)

Author keywords

Bone metastasis; Bone turnover markers; Deoxypyridinoline; Lung cancer

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; DEOXYPYRIDINOLINE; OSTEOCALCIN; TECHNETIUM 99M;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER STAGING; CLINICAL ASSESSMENT; CONTROLLED STUDY; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 42349113782     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-9684(15)31276-1     Document Type: Article

References (25)

1. Demers LM, Costa L, Chinchilli VM, et al. Biochemical markers of bone turnover in patients with metastatic bone disease. Clin Chem. 1995;41(10): 1489-1494.
2. Gayed I, Vu T, Johnson M, et al. Comparison of bone and 2-deoxy-2-[18F] fluoro-D-glucose positron emission tomography in the evaluation of bony metastases in lung cancer. Mol Imaging Biol. 2003;5(1):26-31.
3. Aruga A, Koizumi M, Hotta R, et al. Usefulness of bone metabolic markers in the diagnosis and follow-up of bone metastasis from lung cancer. Br J Cancer. 1997;76(6):760-764.
4. Ebert W, Muley TH, Herb KB, et al. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res. 2004;24(5B):3193-3202.
5. Dodwell DJ. Malignant bone resorption: Cellular and biochemical mechanisms. Ann Oncol. 1992;3(4):257-267.
6. Citrin DL, Hougen C, Zweibel W, et al. The use of serial bone scans in assessing response of bone metastases to systemic treatment. Cancer. 1981;47(4):680-685.
7. Epstein S. Serum and urinary markers of bone remodeling: assessment of bone turnover. Endocr Rev. 1988;9(4):437-449.
8. Fujimoto D, Moriguchi T, Ishida T, et al. The structure of pyridinoline, a collagen crosslink. Biochem Biophys Res Commun. 1978;84(1):52-57.
9. Seibel MJ. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005;26(4):97-122.
10. Eyre DR, Paz MA, Gallop PM. Cross-linking in collagen and elastin. Annu Rev Biochem. 1984;53:717-748.
11. Eyre D. Collagen cross-linking aminoacids. Methods Enzymol. 1987;144: 115-139.
12. Miyamoto KK, McSherry SA, Robins SP, et al. Collagens cross-link metabolites in urine as markers of bone metastases in prostatic carcinoma. J Urol. 1994;151:909-913.
13. Coleman RE, Houston S, James I, et al. Preliminary results of the use of urinary excretion of pyridinium crosslinks for monitoring metastatic bone disease. Br J Cancer. 1992;65:766-768.
14. Robins SP, Black D, Faterson CR, et al. Evaluation of urinary hydroxypyridinium crosslink measurements as resorption markers in metabolic bone diseases. Eur J Clin Invest. 1991;21:310-315.
15. Koga H, Naito S, Koto S, et al. Use of bone turnover marker, pyridinoline cross-linked carboxyterminal telopeptide of type I collagen (ICTP), in the assessment and monitoring of bone metastasis in prostate cancer. Prostate. 1999;39:1-7.
16. Tahtela R, Tholix E. Serum concentrations of type I collagen carboxy-terminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer. Anticancer Res. 1996;16:2289-2293.
17. Miura H, Yamamoto I, Takada M, et al. Diagnostic validity of bone metabolic markers for bone metastasis. Endocr J. 1997;44:751-757.
18. Izumi M, Nakanishi Y, Takayama K, et al. Diagnostic value of bone-turnover metabolites in the diagnosis of bone metastases in patients with lung carcinoma. Cancer. 2001;91:1487-1493.
19. Savas I, Gurkan OU, Savas H, et al. Urine deoxypyridinoline level: an alternative to bone scan in lung cancer? Clin Biochem. 2000;33(7):591-593.
20. Chung JH, Park MS, Kim YS, et al. Usefulness of bone metabolic markers in the diagnosis of bone metastasis from lung cancer. Yonsei Med J. 2005;46:388-393.
21. Christenson RH. Biochemical Markers of Bone Metabolism: an overview. Clin Biochem. 1997;30:573-593.
22. Bataille R, Delmas P, Sany J. Serum bone gla-protein in multiple myeloma. Cancer. 1987;59:329-334.
23. Takeuchi S, Arai K, Saitoh H, et al. Urinary pyridinoline and deoxypyridinoline as potential markers of bone metastasis in patients with prostate cancer. J Urol. 1996;156:1691-1695.
24. Akimoto S, Furuya Y, Akakura K, et al. Comparison of markers of bone formation and resorption in prostate cancer patient to predict bone metastasis. Endocr J. 1998;45:97-104.
25. Garnero P, Buchs N, Zekri J, et al. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer. 2000;82:858-864.